Innovate UK has funded QV Bioelectronics with £630k to start testing their electricity-based brain cancer treatment. They plan on beginning animal testing this year.

Currently, brain tumours are the leading cause of death in both kids and people under 40.

“Innovate UK has funded QV Bioelectronics with £630k to start testing their electricity-based brain cancer treatment“

The majority of treatment options are still in the research stage; this includes anything from drugs to inoculations to implants and more. There is one solution from the United States however it exceeds £20k per month per patient. This also means patients would have to shave their head each month and the clinic would have factor in the use of transcranial cables and large batteries.

Dr. Richard Fu, clinical director of QV Bioelectronics, explained that "in my practice as a neurosurgeon, the best standard of care combining surgery, chemotherapy and radiotherapy still has a desperately poor prognosis, with a 12-month life expectancy and ~3% survival chance after five years. This is what lead me to co-found QV Bioelectronics to improve patient outcomes.”

Chief Executive Officer of QV Bioelectronics, Dr. Chris Bullock, commented that “this significant funding from Innovate UK will support preclinical studies of QV Bioelectronics’ GRACE device, enabling us to take several big strides forwards towards human clinical trials. The highly competitive nature of the grants, with rigorous technical assessment, de-risks follow on venture capital investment.”

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.